Navigation Links
Micromet Expands Committed Equity Financing Facility to $75 Million
Date:12/2/2008

linical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203, which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the issuance of shares of Micromet's common stock under the new CEFF and the registration for resale of the shares to be issued under the CEFF. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that decreases in the price of the Company's common stock could prohibit the Company from being able to access the new CEFF and the ability of Kingsbridge to terminate the CEFF in the event that the Company does not draw down specified amounts under the new CEFF. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2008, filed with the SEC on November 6, 2008, as well as other filings by Micromet with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as a
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014 Capnia, Inc. (NASDAQ: ... of medical diagnostics based on its proprietary Sensalyze™ ... today announced financial results for the third quarter ... "Following the completion of our initial public ... maximize the recently initiated CoSense® commercial launch," said ...
(Date:12/19/2014)... -- Since last month,s FBI shutdown of online drug ... leading online black market for illegal drugs - Evolution ... of drugs and other illegal items.  New numbers from ... in lowering the numbers of drugs and illegal items ... August. But some new sites that have emerged as ...
(Date:12/19/2014)... separating membrane market has witnessed robust development with the ... as a later starter. In 2012, the size of ... billion, with the proportion worldwide soaring to 16.3%. It is ... will continue its growth rate by around 20% in the ... to roughly RMB25 billion. An integrated membrane industrial ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... Oct. 21 Today, Cephalon, Inc. (Nasdaq: ... subscription agreement with ChemGenex Pharmaceuticals Limited (ASX: CXS), an ... the agreement, Cephalon will provide up to A$15 million ... convertible at A$0.50 per share.  This funding will support ...
... FRAZER, Pa., Oct. 21 Cephalon, Inc. (Nasdaq: ... its option to acquire BioAssets Development Corporation (BDC), following ... proof-of-concept study evaluating epidural administration of a tumor necrosis ... 45 patients. Sciatica is a neuropathic inflammatory pain condition ...
Cached Medicine Technology:Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations 2Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations 3Cephalon Exercises its Option to Acquire BioAssets Development Corporation 2Cephalon Exercises its Option to Acquire BioAssets Development Corporation 3Cephalon Exercises its Option to Acquire BioAssets Development Corporation 4
(Date:12/20/2014)... (PRWEB) December 20, 2014 As ... move forward in U.S. courts, Bernstein Liebhard LLP ... suggests that children treated with the medication may ... to breast development and lactation. The study, which ... children and adolescents who began treatment with risperidone, ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men ... and other serious side effects will be consolidated in ... coordinated pretrial proceedings, Wright & Schulte LLC reports. The ... order Friday to transfer 21 Xarelto lawsuits and over ... to the Louisiana district court for coordination by Judge ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with the holidays ... the wayside until Christmas and the New Year are over. ... that burning desire to just escape it all and get ... Telluride with a no-fuss, affordable package. Montrose Days Inn will ... and ensure that all accommodations are met. Plus, everyone has ...
(Date:12/19/2014)... 19, 2014 Silver Dollar City ... record -- for the first time ever, Silver Dollar City ... Guinness World Records 2015, listing the park’s wood coaster Outlaw ... In additional awards announced this week, Silver Dollar City is ... in the US,” USA Today’s 10Best awards for “Best Public ...
(Date:12/19/2014)... The Medspa at Hendrick in Abilene, ... respected cosmetic brand Juvéderm. Voluma XC treats volume loss ... Medspa at Hendrick is pleased to be able to ... to its clients. , Voluma is the first and ... treat the mid-face and cheek area. This non-invasive treatment ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2
... researchers have found that a radical prostatectomy can be ... which run counter the// conventional practice of generally avoiding ... on age, are available today in Urology. ... as well as safer forms of anesthesia and less-invasive ...
... Medical Association (AMA) has said that the scheme proposed to ... ,In July, a scheme was made public by the Council ... by December; this was thought to be need of the ... foreign doctor and the death of 17 patients., ...
... it initially helps in inducing slumber, says a new study.// ... of the night and overall less deep sleep, reported the ... Conroy and other researchers at the University of Michigan examined ... drinking habits and its impact on their sleep. ...
... psychologists have observed an alarming trend in the kids, even those ... like teenagers. The physical and// behavioral changes which marks the teenage ... age of 8 to 12; so the sobriquet ‘tweens’, seems to ... a fancy to own expensive items like cell phones and iPods. ...
... NASA aims to help people control their brain waves. ... ameliorating a wide range of// ailments. NASA developed this training ... later this technique was introduced in Korea in 2003. ... Medical Center adopted this technique, but now it is being ...
... a new study about alcoholism and published the results ... Research.// The study highlighted 3 main points: ... leads to poor-quality sleep later in the night. ... lead to alcoholism. ,· Inaccurate sleep perceptions among ...
Cached Medicine News:Health News:Octogenarians Are Not Too Old for Cancer Surgery 2Health News:Tune Your Brain To Fight Disorders 2Health News:Alcohol Dependence For Sleep Perceptions May Result In Alcoholism 2Health News:Alcohol Dependence For Sleep Perceptions May Result In Alcoholism 3
New!...
...
Mendez Multi-Purpose LASIK Forceps. To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps, Titanium...
The CGPL capsulotomy contact glass was designed by Riquin, Fankhauser et al. for the dissection of opacified posterior lens capsules and membranes in the pupillary and retropupillary space with the Y...
Medicine Products: